Adolor Corporation (NasdaqGM: ADLR) today announced that it will hold a conference call at 8:30 a.m. EDT on Wednesday, August 10, 2011, to discuss the results of its Phase 2 trials of ADL5945 in chronic opioid-induced constipation (OIC).
To participate in the audio portion and have the opportunity to pose questions, dial 866-202-3109 for domestic callers or 617-213-8844 for international callers, and enter Conference ID # 62949696. Investors also can listen to the call live and view a slide presentation by logging on to the Company’s website at www.adolor.com and clicking on “Investor Insights,” then "Calendar of Events."